About Takeda Pharmaceuticals
Takeda Pharmaceuticals is a publicly listed company based in Tokyo (Japan) founded in 1781. Takeda Pharmaceuticals is engaged in developing innovative medicines globally. It operates on a Direct-to-Consumer (D2C) and Professional Services model. The company has 47,450 employees. Takeda Pharmaceuticals has completed 17 acquisitions, including Adaptate Biotherapeutics, Ariad Pharmaceuticals and IDM Pharma. Its website takeda.com draws about 620 thousand monthly visits. Takeda Pharmaceuticals offers products and services including Oveporexton (TAK-861), Plasma-Derived Therapies, and Oncology Treatments. Its focus areas include Pharmaceuticals, Biopharmaceuticals, Biotechnology and Rare Disease Treatments. Its legal entity is Takeda Pharmaceutical Company Limited.
Company details
Takeda Pharmaceuticals is involved in the research, development, and manufacturing of innovative medicines. Focus areas include gastrointestinal and inflammatory diseases, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. Solutions are provided to address unmet medical needs worldwide, with operations spanning multiple countries. Sustainability and corporate responsibility are integrated into the business strategy to enhance climate-resilient health systems.
- Headquarters Tokyo, Japan
- Employees 47,450
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website takeda.com
- Social LinkedIn X YouTube
- Legal Name Takeda Pharmaceutical Co. Ltd.
- Annual Revenue$28.28 B (USD)-1.66as on Mar 31, 2026
- Net Profit-$955.44 M (USD)-241.2as on Mar 31, 2026
- EBITDA$8.46 B (USD)-2.46as on Mar 31, 2026
- Latest Funding Round$30.9B (USD), Debt – Conventional
Nov 2018
- Investors
- Employee Count47,450
- Investments & AcquisitionsAdaptate Biotherapeutics
& 16 more
Associated legal entities of Takeda Pharmaceuticals
Takeda Pharmaceuticals is associated with 3 registered companies on The Company Check. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Takeda Innovations India Private Limited CIN U62099KA2023FTC181372 | Active | 24 Nov 2023 | Bangalore, Karnataka | ₹120 Cr | 154 | 4 | View details |
| Takeda Pharmaceuticals India Private Limited CIN U24239MH2011FTC212891 | Amalgamated | 01 Feb 2011 | Bhiwandi, Maharashtra | ₹8.5 Cr | 1 | 4 | View details |
| Takeda Biopharmaceuticals India Private Limited CIN U51909HR2015FTC055144 | Active | 15 Apr 2015 | Gurgaon, Haryana | ₹727 Cr | 202 | 5 | View details |
Products & Services of Takeda Pharmaceuticals
Takeda Pharmaceuticals offers a comprehensive portfolio of products and services, including Oveporexton (TAK-861), Plasma-Derived Therapies, and Oncology Treatments.
Developed for treating narcolepsy type 1 in patients.
Innovated for chronic rare diseases using plasma technology.
Created to address cancer with innovative therapeutic solutions.
Apps and channels of Takeda Pharmaceuticals
its YouTube channel Takeda has 23.6K subscribers and 30 videos.
Videos from Takeda Pharmaceuticals
The most watched videos on Takeda Pharmaceuticals's YouTube channel, Takeda (23.6K subscribers). Click a video to play it here.
More on Takeda.
Funding Insights of Takeda Pharmaceuticals
- Total Rounds 2
- Last Round Debt – Conventional — $30.9B
- First Round $2.6M
(Mar 2011)
- Investors Count 1
All 2 funding rounds of Takeda Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2018 | $30.9B | Debt – Conventional | – | – | – |
| Mar 2011 | $2.6M | Grant | – | – |
1 investors in total: 1 institutional.
Investors in Takeda Pharmaceuticals
Takeda Pharmaceuticals has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Military Health.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Administers health care and support for military personnel and operations. | health.mil | Falls Church, United States |
Investor details for Takeda Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Takeda Pharmaceuticals
The boards of the 3 registered companies of Takeda Pharmaceuticals currently have 10 directors; the longest-serving is Gopal Agrawal, appointed in 2020. 34 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Gopal Agrawal DIN 08532882 | Director | 02 Mar 2020 | 6 yrs 8 mo | Takeda Pharmaceuticals India Private Limited |
| Anoop Kishore Kamat DIN 09158117 | Director | 23 Apr 2021 | 5 yrs 6 mo | Takeda Biopharmaceuticals India Private Limited, Takeda Pharmaceuticals India Private Limited |
| Rajesh Eric Dmellokamath DIN 09245406 | Director | 31 Jul 2021 | 5 yrs 3 mo | Takeda Pharmaceuticals India Private Limited |
| Serina Magner Fischer DIN 09534518 | Director | 17 Mar 2022 | 4 yrs 7 mo | Takeda Pharmaceuticals India Private Limited |
| Sanjay Patel DIN 10403750 | Director | 24 Nov 2023 | 2 yrs 11 mo | Takeda Innovations India Private Limited |
| Rebecca Jane Kaufmann DIN 10403751 | Director | 24 Nov 2023 | 2 yrs 11 mo | Takeda Innovations India Private Limited |
| Tilak Banerjee DIN 02561263 | Director | 23 Feb 2024 | 2 yrs 8 mo | Takeda Innovations India Private Limited |
| Annapurna Das DIN 08634664 | Director | 04 Jun 2024 | 2 yrs 5 mo | Takeda Biopharmaceuticals India Private Limited |
| Rahul Ganesh Kedia DIN 07187814 | Director | 25 Sep 2024 | 2 yrs 1 mo | Takeda Biopharmaceuticals India Private Limited |
| Anjana Narain DIN 10051184 | Director | 08 Nov 2024 | 2 yrs | Takeda Biopharmaceuticals India Private Limited |
People of Takeda Pharmaceuticals
1052 people are tracked at Takeda Pharmaceuticals (634 in leadership, 11 in board & advisors, 407 in team); the tracked headcount is 47,450.
| Name | Role | Group |
|---|---|---|
Petr Galík | TBS Global Head Of Innovation, Analytics And Automation | Leadership |
Andrew S. Plump | Director, President of Research & Development | Leadership |
Manan Shah | Associate Director Global CMC Regulatory Affairs | Leadership |
Sridevi Ponduru M.D. | Senior Medical Director | Leadership |
Milano Furuta | CFO | Leadership |
Michael Denne | VP US Medical Affairs, Rare Disease And Plasma Derived Therapies | Leadership |
Neeraj Gupta | Executive Director And Head | Leadership |
Teresa Bitetti | President, Global Oncology | Leadership |
Giuseppe Piergiovanni | Head Of Process Engineering For Plasma | Leadership |
Dominic Cirincione | Associate Director, US Advertising And Promotion Regulatory (a&p Excellence) | Leadership |
Simeon William | Senior Human Resource Business Partner - India | Leadership |
Luna Zaru | Director | Leadership |
Julie Kim | Interim Head, Global Portfolio Division | Leadership |
Masato Iwasaki | President, Japan Pharma | Leadership |
Kristi Bond | Media Relations & Operations Head | Leadership |
Krystal Sing | Medical Director | Leadership |
Eileen Burkart Hartman | Senior Director, US Medical Office, Scientific Communications | Leadership |
Russ Gaszak | Head Of Sales - Neuroscience | Leadership |
Lauren Duprey | Chief Human Resources Officer | Leadership |
Nereyda Garcia | Head, Ethics & Compliance, US Business Unit | Leadership |
1032 more people are available in the full profile.
Complete people profiles for Takeda Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Takeda Pharmaceuticals
Takeda Pharmaceuticals is a publicly listed company on the TSE with ticker symbol 4502 in Japan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date14 May 2010
- Listed onNYSE: TAK
- Listed entityTakeda Pharmaceutical Co. Ltd.
- Exchange sectorHealth technology
- ISINJP3463000004
- Share price5,889.00 JPY (-1.24% on the day) · 2026-10-14
- Market capitalisation9,517,738,505,127.00 JPY
- Price to earnings223.0
- EPS (diluted, trailing year)-105.49 JPY
- Dividend yield3.46%
- Volume (last session)3,604,400
Financials of Takeda Pharmaceuticals
Figures of Takeda Biopharmaceuticals India Private Limited, the primary company behind Takeda Pharmaceuticals, for FY 2025. Revenue was ₹727 Cr (-7% year on year). Net profit was ₹23.90 Cr (3% margin). EBITDA was ₹42.89 Cr (6% margin). Revenue has grown at a compounded annual rate of +10% over three years and +6% over five years.
- ₹727 CrRevenue · FY 2025 · -7% YoY
- ₹23.90 CrNet profit · 3% margin
- ₹42.89 CrEBITDA · 6% margin
- ₹216 CrPaid-up capital
- 202Employees (provident fund records)
- +10%Revenue CAGR, 3 years
- +6%Revenue CAGR, 5 years
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 4,510.00B JPY | -152.39B JPY | 1,350.00B JPY |
| 2024 | 4,580.00B JPY | 107.93B JPY | 1,390.00B JPY |
| 2023 | 4,260.00B JPY | 144.07B JPY | 1,260.00B JPY |
| 2022 | 4,030.00B JPY | 317.02B JPY | 1,320.00B JPY |
| 2021 | 3,570.00B JPY | 230.06B JPY | 1,190.00B JPY |
Balance sheet, profit and loss, cash flow and ratios of Takeda Biopharmaceuticals India Private Limited are on its company page.
Detailed financial statements for Takeda Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Takeda Pharmaceuticals
Takeda Pharmaceuticals has strategically engaged in corporate development activities, having acquired 17 companies. Notable acquisitions include Adaptate Biotherapeutics, Ariad Pharmaceuticals and IDM Pharma.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Therapeutics for psoriasis treatment are developed by the company. | Cambridge, United States | 0 | Dec 2022 | $4B | ||
T-cell-based immunotherapies for cancer treatment are developed. | adaptate.com | London, United Kingdom | 2019 | Jan 2022 | •••• | |
Novel enzyme therapeutics for celiac disease are engineered. | pvpbio.com | San Diego, United States | 2015 | Feb 2020 | $330M | |
Rare disease treatments are developed by a specialty biopharmaceutical firm. | shire.com | Dublin, Ireland | 1986 | May 2018 | $60B | |
Sports services are provided to clients in the United Kingdom. | theshirelondon.com | Barnet, United Kingdom | 2007 | May 2018 | $62.33B | |
Allogeneic stem cell-based therapies targeting autoimmune, inflammatory and heart diseases. | tigenix.com | Leuven, Belgium | 2000 | Jan 2018 | $632M | |
Targeted small molecules to treat variety of cancer such as chronic myeloid leukemia, acute lymphoblastic leukemia, lung and biliary. | ariad.com | Cambridge, United States | 1991 | Jan 2017 | $5.2B | |
Natura-alpha is developed for ulcerative colitis clinical trials. | natrogen.com | New York, United States | 2002 | Dec 2013 | •••• | |
PI3K/mTOR pathway inhibitors for cancer treatment were developed. | intellikine.com | San Diego, United States | 2007 | •••• | ||
Vaccines for infectious diseases including dengue and influenza were developed. | inviragen.com | Fort Collins, United States | 2005 | •••• |
Complete acquisition details for Takeda Pharmaceuticals
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Takeda Pharmaceuticals
13 dated milestones of Takeda Pharmaceuticals across 12 years, from founding to its latest funding, stage changes and deals.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $2.6M.
- Acquisition Acquires Natrogen Therapeutics International.
- Acquisition Acquires Ariad Pharmaceuticals.
- Acquisition Acquires TiGenix.
- Acquisition Acquires The Shire London.
- Acquisition Acquires Takeda Pharmaceuticals.
- Funding Latest funding round, Debt – Conventional, of $30.9B.
- Acquisition Acquires PVP Biologics.
- Acquisition Acquires Takeda Pharmaceuticals.
- Acquisition Acquires Takeda Pharmaceuticals.
- Acquisition Acquires Adaptate Biotherapeutics.
- Acquisition Acquires Nimbus Lakshmi.
Web traffic of Takeda Pharmaceuticals
The website of Takeda Pharmaceuticals (takeda.com) receives about 620.1K visits a month and ranks #93,966 among all websites worldwide, #2,700 in Biotechnology and Pharmaceuticals.
- Monthly visits620.1K
▲ 8.3% vs previous month
- Unique visitors308K
per month
- Global rank#93,966
among all websites
- Category rank#2,700
Health · Biotechnology and Pharmaceuticals
- Bounce rate52%
- Pages per visit2.3
- Average visit1 min 14 sec
- DevicesDesktop 48% · Mobile 52%
Websites whose visitors overlap most with Takeda Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| novartis.com | 100% | 948.8K | #58,822 | View details | |
| pfizer.com | 97% | 1.9M | #24,984 | View details | |
careers.lilly.com | careers.lilly.com | 93% | #60,411 | – | |
mytakeda.sharepoint.com | mytakeda.sharepoint.com | 92% | – | ||
takedamed.com | takedamed.com | 91% | #502,209 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Takeda Pharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Takeda Pharmaceuticals
Complete news archive for Takeda Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Takeda Pharmaceuticals
Takeda Pharmaceuticals was founded in 1781 and raised its 1st funding round 230 years after it was founded.
Takeda Pharmaceuticals is headquartered in Tokyo, Japan. It is registered at Tokyo, Tokyo, Japan.
Takeda Pharmaceuticals has 47,450 employees.
Annual revenue of Takeda Pharmaceuticals is $28.28B as on Mar 31, 2026.
Takeda Pharmaceuticals is involved in the research, development, and manufacturing of innovative medicines. Focus areas include gastrointestinal and inflammatory diseases, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. Solutions are provided to address unmet medical needs worldwide, with operations spanning multiple countries. Sustainability and corporate responsibility are integrated into the business strategy to enhance climate-resilient health systems.
Takeda Pharmaceuticals offers Oveporexton (TAK-861), Plasma-Derived Therapies, and Oncology Treatments.
Yes, Takeda Pharmaceuticals is publicly traded on TSE under the ticker symbol 4502.
Takeda Pharmaceuticals has made 17 acquisitions, including Adaptate Biotherapeutics, Ariad Pharmaceuticals, and IDM Pharma.
Takeda Pharmaceuticals has 1 investor. Key investors include Military Health.
Takeda Pharmaceuticals is associated with 3 legal entities: Takeda Biopharmaceuticals India Private Limited, Takeda Innovations India Private Limited, Takeda Pharmaceuticals India Private Limited.
The legal entities of Takeda Pharmaceuticals currently have 12 directors, including Anoop Kishore Kamat, Annapurna Das, Anjana Narain and others.
The website of Takeda Pharmaceuticals receives about 620 thousand visits a month and ranks #93,966 among all websites worldwide.